title: Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
authors.forename: Theognosia
authors.initials: T
authors.lastname: Vergou
authors.forename: Alexander J
authors.initials: AJ
authors.lastname: Stratigos
authors.forename: Eleni M
authors.initials: EM
authors.lastname: Karapanagiotou
authors.forename: Athina E
authors.initials: AE
authors.lastname: Matekovits
authors.forename: Kalliopi D
authors.initials: KD
authors.lastname: Dilana
authors.forename: Sotirios
authors.initials: S
authors.lastname: Tsimboukis
authors.forename: Christina
authors.initials: C
authors.lastname: Antoniou
authors.forename: Vassiliki
authors.initials: V
authors.lastname: Chasapi
authors.forename: Kostas N
authors.initials: KN
authors.lastname: Syrigos
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005140:Eyelashes; D005145:Face; D005260:Female; D006801:Humans; D006983:Hypertrichosis / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors